QIAGEN (QGEN)
(Delayed Data from NYSE)
$42.69 USD
-0.52 (-1.20%)
Updated Oct 17, 2024 04:03 PM ET
After-Market: $42.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.69 USD
-0.52 (-1.20%)
Updated Oct 17, 2024 04:03 PM ET
After-Market: $42.69 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Will Thermo Fisher's (TMO) Failed QIAGEN Deal Cost it a Lot?
by Urmimala Biswas
The COVID-19 tailwinds are significantly stronger than what Thermo Fisher (TMO) had originally expected in March.
Boston Scientific's Voraxaze's MAA Accepted by EMA for Review
by Zacks Equity Research
Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be upbeat about ResMed (RMD) owing to its potential in digital health and consistent high demand for its critical care products.
Amedisys Banks on Coronavirus-Driven Growth Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) has been benefiting from the recent acquisitions of hospice care providers.
EPA Validates NEOGEN's Disinfectant for Use Against COVID-19
by Zacks Equity Research
NEOGEN's (NEOG) BioSentry 904 Disinfectant approved by the EPA for use against the COVID-19-causing SARS-CoV-2 virus.
Omnicell, Pharmaceutical Strategies Enter Acquisition Deal
by Zacks Equity Research
Omnicell (OMCL) expands pharmacy supply chain capabilities for better management of 340B programs through the buyout of PSG's 340B Link business.
Medtronic (MDT) Plans $160 Million R&D Investment in India
by Zacks Equity Research
The newest expansion plan of MEIC will help Medtronic (MDT) advance in the field of pain alleviation and restoration of health.
Medtronic Plans New Acquisition in AI-Driven Diabetes Care
by Zacks Equity Research
Medtronic's (MDT) acquisition of Companion Medical aims to expand service to diabetics using multiple daily injections for diabetes management.
QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up
by Zacks Equity Research
QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.
Is a Surprise Coming for QIAGEN (QGEN) This Earnings Season?
by Zacks Equity Research
QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Canopy Growth (CGC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Orthofix JuniOrtho Plating System Gets Regulatory Clearances
by Zacks Equity Research
Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.
Amedisys Rides on Coronavirus-Led Business Amid Cost Woes
by Zacks Equity Research
Amedisys (AMED) while seeing a drop in MIS visits is experiencing steady recovery in referral volumes.
Quest Diagnostics Gets EUA for Coronavirus Sample Pool Testing
by Zacks Equity Research
Quest Diagnostics (DGX) is riding high on a slew of EUAs for the expanded use of its self-collection molecular diagnostic kit on different platforms.
Rising Coronavirus Cases Spark Lockdown Fears: 5 Defensive Picks
by Zacks Equity Research
Given the current coronavirus scenario, investors can invest in defensive stocks that can return well even during phases of market volatility
Medtronic Banks on Ventilator Sales Amid Coronavirus Crisis
by Zacks Equity Research
Medtronic (MDT) is currently focusing on the geographical diversification of its businesses, apart from product innovation. Also, it demonstrates a strong solvency position.
Integra Reports Organic Sales Drop in Preliminary Q2 Results
by Zacks Equity Research
Integra (IART) projects a severe impact on revenues due to the coronavirus-led economic crisis despite sequential improvement in monthly sales performance throughout the quarter.
Zacks.com featured highlights include: Laboratory Corporation of America, SpartanNash Company, B&G Foods, QIAGEN and Rent-A-Center
by Zacks Equity Research
Zacks.com featured highlights include: Laboratory Corporation of America, SpartanNash Company, B&G Foods, QIAGEN and Rent-A-Center
5 Stocks Trading Near 52-Week High That Can Scale Higher
by Zacks Equity Research
Investors target stocks that display a bullish run. Stocks seeing price strength have a high chance of carrying the momentum forward.
Henry Schein Banks on Dental Consumable Amid Coronavirus Woes
by Zacks Equity Research
Henry Schein (HSIC) seems upbeat about its dental technology business, Henry Schein One.
Henry Schein Medical to Expand in Telemedicine With VisualDx
by Zacks Equity Research
Henry Schein's (HSIC) VisualDx system to be integrated with Medpod's technology infrastructure for improved patient outcome.
QIAGEN (QGEN) Reports Encouraging Preliminary Q2 Results
by Zacks Equity Research
Preliminary net revenues for second-quarter 2020 improved 18-19% at CER.
Hologic Expands Product Portfolio With New Ultrasound System
by Zacks Equity Research
Hologic's (HOLX) latest cart-based ultrasound system enhances efficiency and accuracy to better meet the requirements of breast imagers and optimize patient care.